See more : Atsugi Co., Ltd. (3529.T) Income Statement Analysis – Financial Results
Complete financial analysis of Suven Life Sciences Limited (SUVEN.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Suven Life Sciences Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- EarthRenew Inc. (VVIVF) Income Statement Analysis – Financial Results
- Sanquan Food Co., Ltd. (002216.SZ) Income Statement Analysis – Financial Results
- Rift Valley Resources Corp. (RVR.CN) Income Statement Analysis – Financial Results
- Orica Limited (OCLDY) Income Statement Analysis – Financial Results
- Carbon Revolution Limited (CBR.AX) Income Statement Analysis – Financial Results
Suven Life Sciences Limited (SUVEN.BO)
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.93M | 135.39M | 118.44M | 134.78M | 144.15M | 2.76B | 6.13B | 5.38B | 5.00B | 5.21B | 5.10B | 2.58B | 2.04B | 1.50B | 1.29B | 1.41B | 1.20B | 1.13B | 901.11M | 662.40M |
| Cost of Revenue | 8.24M | 255.32M | 255.75M | 229.07M | 232.33M | 1.19B | 2.42B | 2.32B | 2.65B | 2.45B | 1.90B | 1.22B | 1.02B | 549.64M | 588.91M | 674.12M | 605.55M | 549.15M | 415.48M | 293.15M |
| Gross Profit | 108.69M | -119.93M | -137.31M | -94.28M | -88.18M | 1.57B | 3.71B | 3.06B | 2.34B | 2.76B | 3.20B | 1.36B | 1.02B | 954.70M | 704.20M | 734.20M | 594.26M | 583.48M | 485.64M | 369.25M |
| Gross Profit Ratio | 92.95% | -88.58% | -115.93% | -69.95% | -61.17% | 56.84% | 60.51% | 56.81% | 46.86% | 52.93% | 62.69% | 52.80% | 49.81% | 63.46% | 54.46% | 52.13% | 49.53% | 51.52% | 53.89% | 55.74% |
| Research & Development | 1.14B | 1.15B | 1.06B | 710.27M | 1.03B | 1.19B | 796.87M | 825.08M | 903.52M | 559.63M | 479.48M | 346.93M | 330.49M | 311.44M | 341.51M | 294.60M | 201.69M | 190.02M | 195.67M | 117.87M |
| General & Administrative | 27.11M | 25.35M | 24.94M | 21.83M | 9.73M | 65.26M | 103.02M | 86.80M | 19.60M | 81.21M | 140.17M | 263.20M | 226.95M | 111.83M | 112.57M | 114.83M | 431.10K | 504.31K | 8.10M | 55.76M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.75M | 51.11M | 47.64M | 39.64M | 27.36M | 67.12M | 15.23M | 0.00 | 0.00 | 0.00 | 0.00 | 20.63M | 21.50M | 15.84M | 21.72M |
| SG&A | 27.11M | 25.35M | 24.94M | 21.83M | 9.73M | 101.02M | 154.14M | 134.44M | 19.60M | 108.57M | 207.29M | 278.43M | 226.95M | 111.83M | 112.57M | 114.83M | 21.06M | 22.00M | 23.94M | 77.48M |
| Other Expenses | -1.06B | 129.00K | 130.00K | 77.54M | 140.36M | 3.30M | 529.00K | 1.96M | 894.00K | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 67.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 109.75M | 1.45B | 1.38B | 966.38M | 1.34B | 1.82B | 1.93B | 1.97B | 1.74B | 1.27B | 1.10B | 908.40M | 841.36M | 922.15M | 614.63M | 550.36M | 511.14M | 455.09M | 404.31M | 313.58M |
| Cost & Expenses | 1.34B | 1.45B | 1.38B | 966.38M | 1.34B | 3.01B | 4.35B | 4.29B | 4.39B | 3.72B | 3.00B | 2.13B | 1.87B | 1.47B | 1.20B | 1.22B | 1.12B | 1.00B | 819.79M | 606.74M |
| Interest Income | 164.25M | 64.16M | 11.26M | 69.79M | 132.13M | 11.15M | 8.92M | 6.89M | 24.79M | 23.39M | 14.72M | 2.35M | 1.46M | 0.00 | 0.00 | 0.00 | 3.68M | 1.49M | 810.63K | 1.40M |
| Interest Expense | 2.99M | 4.15M | 5.32M | 8.15M | 4.87M | 12.01M | 28.16M | 37.64M | 40.65M | 28.61M | 61.89M | 135.09M | 99.09M | 61.05M | 49.40M | 67.49M | 45.71M | 23.38M | 12.98M | 6.07M |
| Depreciation & Amortization | 58.16M | 65.43M | 43.93M | 43.46M | 41.69M | 141.97M | 247.64M | 276.46M | 239.53M | 242.12M | 114.90M | 104.67M | 85.45M | 79.06M | 76.97M | 71.42M | 66.05M | 40.14M | 47.26M | 41.04M |
| EBITDA | -992.78M | -1.11B | -1.17B | -721.87M | -1.02B | 162.67M | 2.25B | 1.57B | 1.27B | 1.82B | 2.22B | 557.84M | 261.30M | -1.39B | 163.43M | 189.88M | 175.35M | 171.07M | 125.18M | 107.25M |
| EBITDA Ratio | -849.05% | -880.94% | -1,022.05% | -536.96% | -709.33% | -1.90% | 33.45% | 25.04% | 21.93% | 34.45% | 43.19% | 21.63% | 12.80% | -92.58% | 12.88% | 13.94% | 14.24% | 15.10% | 14.68% | 15.77% |
| Operating Income | -1.23B | -1.32B | -1.26B | -838.73M | -1.17B | -280.86M | 1.68B | 1.06B | 856.46M | 1.55B | 2.09B | 453.17M | 175.85M | -1.47B | 89.58M | 124.84M | 104.82M | 130.93M | 85.06M | 63.43M |
| Operating Income Ratio | -1,048.35% | -974.76% | -1,065.38% | -622.28% | -811.70% | -10.18% | 27.35% | 19.65% | 17.15% | 29.80% | 40.94% | 17.57% | 8.61% | -97.84% | 6.93% | 8.86% | 8.74% | 11.56% | 9.44% | 9.58% |
| Total Other Income/Expenses | 165.04M | 26.75M | -41.25M | -18.81M | 106.03M | -76.12M | -312.13M | -318.42M | -261.19M | -283.21M | -74.83M | -124.66M | -84.43M | -48.62M | -52.52M | -73.88M | -41.23M | -20.84M | -16.38M | 4.48M |
| Income Before Tax | -1.06B | -1.18B | -1.22B | -774.74M | -1.06B | 1.56M | 1.96B | 1.23B | 975.84M | 1.52B | 2.03B | 328.52M | 91.42M | 32.55M | 37.06M | 50.97M | 63.59M | 107.55M | 64.95M | 60.14M |
| Income Before Tax Ratio | -907.21% | -873.52% | -1,029.99% | -574.81% | -738.14% | 0.06% | 31.92% | 22.87% | 19.54% | 29.10% | 39.73% | 12.74% | 4.48% | 2.16% | 2.87% | 3.62% | 5.30% | 9.50% | 7.21% | 9.08% |
| Income Tax Expense | -10.02M | 4.60M | 4.42M | -53.23M | -121.83M | 240.60M | 718.38M | 358.83M | 257.36M | 428.04M | 585.80M | 20.13M | -52.21M | -71.45M | -32.95M | -20.26M | -19.94M | -5.09M | 1.07M | 36.08M |
| Net Income | -1.05B | -1.18B | -1.22B | -721.51M | -942.18M | -239.04M | 1.24B | 871.87M | 718.49M | 1.09B | 1.44B | 308.40M | 143.62M | 102.32M | 70.01M | 71.22M | 83.53M | 112.64M | 63.87M | 24.06M |
| Net Income Ratio | -898.63% | -873.52% | -1,029.99% | -535.31% | -653.62% | -8.67% | 20.19% | 16.20% | 14.38% | 20.88% | 28.25% | 11.96% | 7.03% | 6.80% | 5.41% | 5.06% | 6.96% | 9.95% | 7.09% | 3.63% |
| EPS | -4.82 | -5.42 | -5.59 | -3.31 | -4.32 | -1.10 | 8.95 | 6.31 | 5.17 | 8.33 | 11.37 | 2.43 | 1.13 | 0.81 | 0.55 | 0.57 | 0.66 | 0.90 | 2.35 | 0.22 |
| EPS Diluted | -4.82 | -5.42 | -5.59 | -3.31 | -4.32 | -1.10 | 8.95 | 6.31 | 5.17 | 8.33 | 11.37 | 2.43 | 1.13 | 0.81 | 0.55 | 0.57 | 0.66 | 0.90 | 2.35 | 0.22 |
| Weighted Avg Shares Out | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M |
| Weighted Avg Shares Out (Dil) | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M | 218.07M |
Source: https://incomestatements.info
Category: Stock Reports